InvestorsHub Logo
Followers 51
Posts 9157
Boards Moderated 1
Alias Born 10/25/2007

Re: FooBarAndGrill post# 12187

Tuesday, 11/08/2022 12:12:30 AM

Tuesday, November 08, 2022 12:12:30 AM

Post# of 13542
REV 3.4B, EPS 2.53

-2022 est 18 - 19B$

-Pipeline 48 programs, 45 categories, 35 are in clinical trials

-PVC PII data expected 4Q22

-RSV PIII data expected this winter

-FLU PIII data 1Q23

Cash/cash equivalent at end of 3Q, 17B$

How money was spent

-Repurchase 24M share for 2.9B$ (complete) reduces outstanding shares (405M to 387M)

-Started a 2d buyback plan (3B$) as announced in AUG22

-Reinvested 820M$ in R&D (pipeline)

-Losses, 333M$ write off on CV19 product, and 102M$ from canceled purchase agreements

$MRNA multibaggers
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News